Rigel Pharmaceuticals | Capitale Ordinario





Capitale Ordinario Cambiamento Data
Agenus USD 266K 30K 2025-03
Amgen USD 539M 1000K 2025-12
Anika Therapeutics USD 143K 1000 2025-03
Arrowhead Research USD 135.7M 2.44M 2025-09
AstraZeneca USD 1.55B 206K 2025-12
BioMarin Pharmaceutical USD 192.3M 201K 2025-12
Bristol-Myers Squibb USD 2.04B 1.74B 2025-09
Celldex Therapeutics USD 66.55M 102K 2025-12
Daiichi Sankyo JPY 1.85B 9K 2025-12
Eli Lilly USD 946.83M 354.23M 2025-06
Halozyme Therapeutics USD 117.78M 259K 2025-12
Heron Therapeutics USD 1.52M 14K 2024-09
Intrexon USD 0 0 2024-06
Ionis Pharmaceuticals USD 161.97M 836K 2025-12
Karyopharm Therapeutics USD 13K 0 2024-09
Ligand Pharmaceuticals USD 19.66M 19.64M 2025-09
MacroGenics USD 63.26M 62.63M 2025-09
Neurocrine Biosciences USD 100.1M 400K 2025-12
Pfizer USD 5.69B 1000K 2025-09
Regeneron Pharmaceuticals USD 105.3M 1.1M 2025-09
Rigel Pharmaceuticals USD 17K 158K 2024-06
Ultragenyx Pharmaceutical USD 96.44M 88K 2025-09
Veracyte USD 79.05M 377K 2025-12


Rigel Pharmaceuticals Capitale Ordinario - Valori correnti, dati storici, previsioni, statistiche, grafici e calendario economico - Mar 2026.